Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS

Valion Bio, Inc.

License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.
Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.
Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.
Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.
Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days.

item 1.01 item 5.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Valion Bio, Inc.: Filed Certificate of Designation for Series A Non-Voting Convertible Preferred Stock establishing rights, preferences, and limitations (effective 2025-02-10).

Change: charter amendment
Effective: 2025-02-10

Exact text from the filing

On February 10, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the License Agreement referenced in Item 1.01 above.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-018419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.